Granted Patent B2

US 12,338,463 · App. 17/181,657 · Granted Jun 24, 2025

Inventors: Russell Garlick (Needham, MA); Catherine Huang (Elkridge, MD); Bharathi Anekella (Clarksburg, MD); Jonathan Li (Chestnut Hill, MA)

Assignee: LGC Clinical Diagnostics, Inc.

C12N7/00C12N15/86C12Q1/70C12N2740/16021C12N2740/16022C12N2740/16031C12N2760/16022C12N2760/16031C12N2770/36121C12N2770/36143

Abstract

Claims (46)

1. A method of testing a diagnostic assay, comprising performing the diagnostic assay on a control comprising replication deficient recombinant Sindbis virus particles comprising an RNA genome comprising:

an open reading frame (ORF) encoding functional Sindbis non-structural proteins; and

a heterologous RNA sequence comprising a non-Sindbis RNA virus sequence or a retrovirus sequence; wherein the non-Sindbis virus sequence is an Ebolavirus sequence, a SARS virus sequence, a West Nile virus sequence, a Zika virus sequence, a poliovirus sequence or a measles virus sequence;

wherein the diagnostic assay is a nucleic acid amplification based diagnostic assay or a nucleic acid sequencing based diagnostic assay comprising:

a) performing a lysis step and/or a nucleic acid extraction step on the composition comprising the replication deficient recombinant Sindbis virus particles; and

b) performing a nucleic acid amplification step or performing a nucleic acid sequencing step on RNA extracted from the replication deficient recombinant Sindbis virus particles; and

wherein the diagnostic assay detects the presence or amplification of an RNA virus or a retrovirus; and the diagnostic assay is valid if the heterologous RNA sequence or its amplification is detected.

2. The method according to claim 1 , wherein the ORF encoding functional Sindbis non-structural proteins:

(a) is located 5′ of the heterologous RNA sequence; and/or

(b) has a nucleotide sequence that is at least 90% identical to nucleotides 1-7648 of SEQ ID NO: 1; and/or

(c) has a nucleotide sequence of nucleotides 1-7648 of SEQ ID NO: 1.

3. The method according to claim 1 , wherein:

(a) the RNA genome lacks a sequence encoding a functional version of one or more of the Sindbis structural proteins, optionally wherein the RNA genome lacks an RNA sequence encoding a functional Sindbis structural protein; or

(b) the heterologous RNA sequence replaces the ORF encoding the Sindbis structural proteins in the RNA genome.

4. The method according to claim 1 , wherein:

(a) the non-structural protein ORF encodes a nsP1 protein, a nsP2 protein, a nsP3 protein and a nsP4 protein; and/or

(b) the RNA genome comprises a 26S subgenomic promoter at the 3′ end of the ORF encoding the Sindbis non-structural proteins; and/or

(c) the heterologous RNA sequence comprises a non-Sindbis RNA virus sequence or a retrovirus sequence.

5. The method according to claim 1 , wherein:

(a) the heterologous RNA sequence comprises one or more, or at least 5, or at least 10 mutations that convey drug resistance when they occur in the non-Sindbis RNA virus or the retrovirus; and/or

(b) the heterologous RNA sequence comprises at least 100 bp, or 100-330 kb of a non-Sindbis RNA virus sequence or a retrovirus sequence; and/or

(c) the heterologous RNA sequence comprises a non-Sindbis RNA virus sequence or a retrovirus sequence.

6. The method according to claim 1 , wherein heterologous RNA sequence comprises a non-Sindbis RNA virus sequence and wherein the non-Sindbis RNA virus sequence is:

(a) a Zaire ebolavirus sequence, a Bundibugyo ebolavirus sequence, a Reston ebolavirus sequence, a Sudan ebolavirus sequence or a Tai Forest ebolavirus sequence;

(b) a Zaire ebolavirus sequence;

(c) an Ebolavirus sequence wherein the Ebolavirus sequence comprises at least a portion of an Ebolavirus GP gene sequence, an Ebolavirus NP gene sequence or an Ebolavirus VP24 gene sequence;

(d) an Ebolavirus sequence wherein the heterologous RNA sequence does not encode a functional Ebola protein, optionally wherein the heterologous RNA sequence encodes truncated Ebola proteins, Ebola proteins with frame-shift mutations or Ebola protein sequences lacking a start codon; or

(e) a Zaire ebolavirus sequence wherein the heterologous RNA sequence comprises a sequence at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 3 optionally wherein the heterologous RNA sequence comprises SEQ ID NO: 2 or SEQ ID NO: 3.

7. The method according to claim 1 , wherein the RNA genome comprises:

(a) a nucleotide sequence that is at least 90% identical to SEQ ID NO: 9 or SEQ ID NO: 10;

(b) SEQ ID NO: 9 or SEQ ID NO: 10;

(c) a nucleotide sequence that is at least 90% identical to either nucleotides 1-3446 of SEQ ID NO: 15, nucleotides 3294-5575 of SEQ ID NO: 15, nucleotides 5425-7722 of SEQ ID NO: 15, or nucleotides 7542-10272 of SEQ ID NO: 15; or

(d) either nucleotides 1-3446 of SEQ ID NO: 15, nucleotides 3294-5575 of SEQ ID NO: 15, nucleotides 5425-7722 of SEQ ID NO: 15, or nucleotides 7542-10272 of SEQ ID NO: 15.

8. The method according to claim 1 , wherein the diagnostic assay is for the detection of an RNA virus or a retrovirus.

9. The method according to claim 8 , wherein the RNA virus is an enveloped non-Sindbis RNA-containing virus or a retrovirus.

10. The method according to claim 8 , wherein the virus is:

(a) Ebolavirus;

(b) a SARS virus;

(c) a hepatitis C virus;

(d) a West Nile virus;

(e) a Zika virus;

(f) a poliovirus; or

(g) a measles virus.

11. The method according to claim 1 , wherein the heterologous RNA sequence comprises:

(a) at least 10, at least 50, at least 100, at least 150, at least 200, at least 300, at least 350, at least 400, at least 450, at least 500, at least 600, at least 650, at least 700, at least 750, at least 800, at least 850, at least 900, at least 950, at least 1000, at least 1100, at least 1200, at least 1300, at least 1400, at least 1500, at least 1600, at least 1700, at least 1800, at least 1900, or at least 2000 bp of a non-Sindbis RNA virus sequence or a retrovirus sequence; or

(b) 100-300 bp or 100-200 bp of a non-Sindbis RNA virus sequence or a retrovirus sequence.

Assignments (2)

Continuity (3)

References Cited (24)